Newsfeed
Source-grounded intelligence on synbio and synbio funding, regulatory milestones, deployments, and policy.
Cellectis Drops CAR-T for In Vivo Gene Editing
Cellectis exits lasme-cel and eti-cel, pivoting to TALE-based in vivo editing with 90% PCSK9 reduction in humanized mice.
Read →Cellectis Drops lasme-cel, eti-cel for APOC3/PCSK9 Editing
Cellectis exits lasme-cel and eti-cel to focus on LNP-delivered APOC3 and PCSK9 editors; CLLS drops 41.61% on the news.
Read →Teijin and Shinshu University Target CAR-T Mfg Gap in Japan
Teijin, Teijin Regenet, and Shinshu University Hospital form joint R&D pact to automate CAR-T manufacturing in Japan.
Read →CRISPR Hits 100% Editing Efficiency in Lisianthus
Chinese researchers achieve 100% CRISPR editing efficiency in whole lisianthus plants, ending three decades of transformation failure.
Read →306 Gene-Editing Trials Tracked in CMN Q2 2026 Database
CMN Intelligence counts 306 publicly disclosed gene-editing trials as of July 2026, with the US and China leading by trial count.
Read →AstraZeneca 600-µL RoboColumns Match Bench Scale for bsAb Purification
AstraZeneca shows 600-µL RoboColumns match ~20-mL bench-scale chromatography for bsAb process characterization.
Read →Editas Hires Dan Ory as CMO to Push EDIT-401 to Clinic
Editas Medicine names Dan Ory, M.D. as CMO to lead EDIT-401 clinical development for hyperlipidemia.
Read →CTX310 CRISPR Cuts LDL 52.5% at 12 Months in Phase I
Cleveland Clinic's Phase I trial shows CTX310 CRISPR therapy cuts LDL 52.5% and triglycerides 47.8% at 12 months, zero serious adverse events.
Read →RT-qPCR Artifact Inflates CRISPR RNA Knockdown Data
A Nature Biotechnology study identifies a pervasive RT-qPCR artifact that systematically overstates RNA knockdown by CRISPR tools.
Read →Beam Therapeutics Hires CCO Ahead of 2027 Risto-cel Launch
Beam Therapeutics names Eric Foster CCO as it targets a 2027 risto-cel launch, drawing on his $2.75B Horizon franchise record.
Read →ArsenalBio Pivots to In Vivo CAR T, Cuts Workforce
ArsenalBio exits autologous solid tumor CAR-T, pivots to in vivo T cell therapy targeting hematologic and autoimmune disease.
Read →CTX310 CRISPR Lipid Data Hold at 1 Year in NEJM
CTX310 CRISPR-Cas9 therapy targeting ANGPTL3 shows durable lipid reduction through 1 year, clearing path to phase 1b.
Read →Nerai Bioscience Raises CHF 500K for AI CRISPR Engineering
Nerai Bioscience raised CHF 500K to build AI-driven CRISPR tool libraries targeting 8 rare disease pipelines from a University of Zurich spinout.
Read →CD19 CAR-T Puts Refractory RA Into Remission in Phase 1
Charité's COMPARE trial: 3 of 6 refractory RA patients in medication-free remission after single CD19 CAR-T infusion.
Read →ÄIO and TFTAK Win €1.94M for Microbial Oil Fermentation
Estonian biotech ÄIO and TFTAK secure €1.94M to digitize microbial oil production from food and wood side-streams.
Read →CTX310 Cuts LDL 53% With One Dose at One Year
Single CTX310 infusion sustains 53% LDL and 48% triglyceride reductions at one year in 15 patients — NEJM data published Aug 28.
Read →$200 Bioreactor Kit Targets US Biomanufacturing Workforce Gap
BioMADE, Novonesis, and Iowa State are building a ~$200 bioreactor kit for high schools to close the biomanufacturing talent gap.
Read →SynGenSys CHO.SET 2.0 Hits 4x Antibody Productivity
SynGenSys CHO.SET 2.0 synthetic promoters deliver over 4x antibody productivity and titers exceeding 2 g/L in fed-batch flask models.
Read →IBioIC Awards £10,000 to Scale Biomanufacturing at 300 L Fermenter
IBioIC offers £10,000 grants to scale biobased processes at a 300 L Heriot-Watt fermenter. Applications closed Sept 1.
Read →DSB-Free CRISPR: Base and Prime Editing Enter the Clinic
Third-generation gene editing ditches double-strand breaks, cutting genotoxicity risks that blocked CRISPR-Cas9 from broad clinical use.
Read →